GP
BMRN icon

GLG Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

GLG Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-39,508
Closed -$3.65M – 377
2016
Q3 		$3.65M Buy
+39,508
New +$3.72M 0.11% 216
2014
Q1 		– Sell
-768
Closed -$54K – 351
2013
Q4 		$54K Buy
+768
New +$52.2K ﹤0.01% 191
2013
Q3 		– Sell
-35,315
Closed -$1.97M – 182
2013
Q2 		$1.97M Buy
+35,315
New +$2.2M 0.08% 178

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GLG Partners's BMRN Position: Q4 2016 in Review

GLG Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2016, closing a stake of 39,508 shares — an estimated $3.65M sold.

GLG Partners first reported a position in BMRN in Q2 2013 and held it in 3 quarters. The position peaked at $3.65M in Q3 2016. 415 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

  • GLG Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • GLG Partners sold 39,508 BioMarin Pharmaceuticals shares in Q4 2016, an estimated $3.65M.
  • GLG Partners first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • GLG Partners's BioMarin Pharmaceuticals position peaked at $3.65M in Q3 2016.
  • 415 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on GLG Partners's 13F filing for Q4 2016, filed 14 Feb 2017.